A股異動丨億帆醫藥漲停 化藥注射劑一致性評價加速
格隆匯10月22日丨億帆醫藥(002019.SZ)漲停,報14.7元,成交6.2億元,總市值181億元。近日國家藥監局就《化學藥品注射劑仿製藥質量和療效一致性評價技術要求(徵求意見稿)、《已上市化學藥品注射劑仿製藥質量和療效一致性評價申報資料要求(徵求意見稿)》公開徵求意見。這也意味着,備受關注的化學藥品注射劑一致性評價正越走越近。億帆醫藥主要經營中成藥、化學原料藥、化學藥製劑、 抗生素、生化藥品、生物製品、診斷藥品。安信證券此前發佈研報表示,今年億帆醫藥的化學制劑板塊預計實現淨利潤約5億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.